We conducted a retrospective analysis to evaluate outcomes of haploidentical transplantation in adult severe aplastic anaemia (SAA) patients. Fifty-one adults received haploidentical transplantation between May 2011 and December 2016. Patients were administered busulfan (Bu), cyclophosphamide (Cy) and anti-thymoglobulin (ATG) as conditioning regimens, followed by bone marrow and peripheral blood transplantation. The patients' median age was 25 years. Forty-nine patients survived for more than 28 days and all achieved donor myeloid engraftment. The median time for myeloid engraftment and platelet recovery was 13 days (range, 10-21) and 17.5 (range, 7-101) days. The cumulative incidence (CI) of grade II-IV and III-IV acute GvHD) was 20.00 ± 0.33% and 6.00 ± 0.12%, respectively. The incidence of chronic GvHD was 14.00 ± 0.36% and 25.90 ± 0.71%, and that of moderate-severe chronic GvHD was 2.51 ± 0.06% and 6.92 ± 0.25% at 1 and 3 years, respectively. The 3-year estimated overall survival and failure-free survival were both 83.5 ± 5.4% with a median follow-up of 21.1 months. Multivariate analysis showed hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score of ⩾3 was significantly associated with worse outcome. Haploidentical transplantation conditioning including Bu/Cy/ATG was a safe and effective strategy for adult SAA patients, and HCT-CI might be an outcome predictor in these patients.
INTRODUCTION
Severe aplastic anaemia (SAA) is a life-threatening disorder characterized by peripheral blood pancytopenia due to bone marrow failure, and inappropriate treatment can significantly increase mortality risk among patients. 1, 2 Currently, allogeneic stem cell transplantation (allo-SCT) is the only curative approach available. Patients lacking suitable HLA-matched related donors (MRD) have other options such as immunosuppressive therapy or transplantation from an alternative donor. Although current guidelines recommend immunosuppressive therapy for these patients, 3 ,4 the event-free or failure-free survival (FFS) of immunosuppressive therapy is only 30-40% because of late complications, including relapse and secondary clonal disease. 1, 5 In recent years, transplantations from both HLA-matched unrelated donor and haploidentical donor (HID) have greatly progressed because of modifications implemented to the conditioning regimen and improvements in the supportive care provided. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The results of haploidentical transplantation in particular have been quite promising in SAA (3-year FFS of 85.0% in upfront cohort or 86.8% in salvage cohort), and were comparable to those of the MRD transplantations. 16, 17 Multicentre studies from China have reported promising results with HID-SCT following the inclusion of a conditioning regimen consisting of busulfan (Bu), cyclophosphamide (Cy) and anti-thymoglobulin (ATG) that was considered to have more potent immunosuppressive activities and produce less regimen-related toxicity. 9, 16, 17 It is well known that the patient's age at the time of transplant is a strong predictor of outcomes following allo-SCT. [18] [19] [20] [21] Better survival rates were documented in children and young adolescents than in older patients because of decreased incidence of transplantation-related mortality (TRM). 18, 22 However, reports of haploidentical transplantation in SAA adults are rare. Although previous studies have investigated the application of various conditioning regimens in an effort to improve outcomes in adult patients receiving transplants from MRD or matched unrelated donor, 22, 23 the outcome of HID-SCT using the Bu/Cy/ATG conditioned regimen in adult SAA patients remains unknown. In addition to identifying the independent factors affecting outcome of HID-SCT conditioned with Bu/Cy/ATG therapy, the safety and efficacy of this regimen in SAA adults also require further investigation. The objective of our study was to address these issues, via analysing the prognostic and long-term outcomes of adult patients with SAA following treatment with HID-SCT using Bu/Cy/ATG conditioning regimen.
SUBJECTS AND METHODS Patients
We retrospectively reviewed the outcomes of 51 consecutive adult patients with SAA who had received HID-SCT treatment with the Bu/Cy/ ATG conditioning regimen without in vitro T-cell depletion from May 2011 to December 2016 at the Peking University People's Hospital. The patients 1 included in the study were ⩾ 18 years, diagnosed with either SAA or very severe aplastic anaemia (vSAA) based on Camitta's criteria, 24 and had undergone transplantation after demonstrating adequate organ function and performance status. Patients with congenital aplasia including Fanconi anaemia, Diamond-Blackfan anaemia or Dyskeratosis congenita were excluded from the study. All eligible patients had provided written informed consent before receiving HID-SCT. The study was approved by the Institutional Review Board of Peking University. The therapeutic benefits of our treatment regimen for 27 of these patients were previously reported in our multicentre studies; 16, 17 in the present study, we followed up the outcome of these patients.
Transplantation procedures
The transplant procedure, including the conditioning regimen, GvHD prophylaxis, stem cell collection and supportive care, have been described in detail elsewhere. 9, 16, 17, 25, 26 The regimen composed of Bu (0.8 mg/kg, four times on day − 7 and − 6, respectively), Cy (50 mg/kg, once on day − 5, − 4, − 3 and − 2, respectively) and rabbit ATG (Sangstat, Lyon, France, 2.5 mg/kg, once on day − 5, − 4, − 3 and − 2, respectively) was administered intravenously.
The GvHD prophylaxis consisted of ciclosporin (CsA), mycophenolate mofetil (MMF) and short-term methotrexate (MTX). ciclosporin (3 mg/kg/ day), divided into doses to achieve the target concentration of 200-250 ng/mL, was administered intravenously from day − 9. Patients were shifted to oral CsA based on their tolerance. The target concentration of CsA was required for up to 1-year post-SCT, and then tapered and discontinued over the following 2-3 months if no GvHD was identified. MMF (0.5 g, q12h) was administered orally from day − 9, the dose was halved on day +30 and then discontinued on day +60. An MTX dose of 15 mg/m 2 was administered intravenously on day +1, with a further dose of 10 mg/m 2 on day +3, +6 and +11, respectively. Both donor and stem cell harvesting, as well as the management of acute and chronic GvHD were in accordance with our previous studies. 9, 25, 26 Antimicrobial prophylaxis consisting of norfloxacin, caspofungin and sulfamethoxazole/trimethoprim was administered at the start of the conditioning treatment. CMV prophylaxis consisted of intravenous ganciclovir until day −2. Following graft infusion, oral acyclovir was administered for the prophylaxis of Herpes virus. After transplantation, and until hospital discharge, patients were tested for CMV infection twice a week using a real-time PCR assay. The patients were treated with either ganciclovir or foscarnet if CMV viraemia was detected. Details of the supportive care provided have been previously described. 9, 25, 26 Definition and evaluation Neutrophil engraftment was defined as three consecutive days with an ANC of 0.5 × 10 9 /L. Platelet recovery was defined as seven consecutive days with an absolute platelet count of 20 × 10 9 /L, without the aid of transfusions. Full donor chimerism was defined as the presence of 495% donor hematopoietic cells, evaluated by FISH (for sex-mismatched pairs) or STR analysis (for sex-matched pairs).
Primary or secondary graft failure (GF), overall survival (OS), FFS and TRM were defined as described elsewhere. 9, 16 Acute (aGvHD) and chronic GvHD were diagnosed and graded as per the criteria described previously. 27, 28 regimen-related toxicity was evaluated according to the Seattle criteria. 29 Pre-transplant comorbidities of patients were assessed, and categorized according to hematopoietic cell transplantation-specific comorbidity index (HCT-CI). 30 
Statistical analysis
The end-point of the last follow-up for all surviving patients was 1 April 2017. Engraftment, GvHD, OS and FFS were calculated from the first graft infusion. Subjects who received grafts were included in the cumulative incidence (CI) analysis of engraftment, GvHD and early infection. The survival curves for OS and FFS were plotted using the Kaplan-Meier method. The curves for engraftment and GvHD were plotted according to CI estimates using the competing risk model. We considered death without engraftment as the competing event for engraftment, and death without GvHD as the competing event for GvHD. The log-rank test was used to identify prognostic factors. Univariate analyses and Cox multivariate analyses were used to determine predictors of survival outcomes. In multivariate analysis, all factors with Po0.1 in univariate analysis were included in the Cox regression model with a backward stepwise model as the selection method. The SPSS statistical software package version 13.0 (SPSS Inc., Chicago, IL, USA) was used in all our analyses. The R version 2.6.1 (http://www.r-project.org) software was used for competing risks analysis. Po0.05 was considered as statistically significant.
RESULTS

Basic characteristics of the patient cohort
The demographic and transplantation characteristics of the study cohort are summarized in Table 1 . The median age of the 51 patients (32 male patients) receiving allo-SCT for SAA was 25 years (range, 18-45 years). The majority of patients (72.5%) had received immunosuppressive therapy, including the administration of ATG/ CsA (9 cases) and CsA (28 cases), respectively. The median pre-SCT serum ferritin was 2000 ng/mL (range, 672.7-20251 ng/mL). Four patients (7.8%) had a HCT-CI of ⩾ 3. At a median of 8 months (range, 1-264) post SAA diagnosis, the patients received HID-SCT with a median 8. Abbreviations: AA = aplastic anemia; HCT-CI = hematopoietic cell transplantation-specific comorbidity index; MNC = mononuclear cell; SAA = severe aplastic anaemia; SCT = stem cell transplantation.
after Table 1 also includes details of graft subtypes and donor characteristics.
Engraftment and GvHD
Only 50 patients were included in the analysis of engraftment, because one of the patients had died from cardiotoxicity on day 01 before the graft infusion. All patients achieved neutrophil engraftment at a median of 13 days (range, 10-21) and they all achieved complete donor chimerism confirmed on day +30 after transplantation, apart from one patient (2.0%) who died of cardiotoxicity on day +3. The CI of neutrophil engraftment was 98.00 ± 0.01%. Platelet recovery of more than 20 × 10 9 /L required a median of 17.5 days (7-101 days) with the CI of 96.00 ± 0.13%. Graft failure, primary or secondary, was not seen in any of the patients.
At a median of 23 days (range, 11-88), 10 of 49 patients with successful engraftment experienced an acute grade II-IV GvHD. Of these, seven patients (14.3%) had grade II, while three (6.1%) had grade IV aGvHD. The CI of grade II-IV and III-IV aGVHD were 20.00 ± 0.33% and 6.00 ± 0.12%, respectively.
Forty-five patients survived for more than 100 days. Chronic GvHDs were observed in eight patients (17.8%) at a median of 9.3 months (range, 3.8-21.9), including six (13.3%) with mild and two (4.4%) with moderate chronic GvHD. The CI at 1 and 3 years of chronic GvHD were 14.00 ± 0.36% and 25.90 ± 0.71%, respectively, and that of moderate-severe chronic GVHD were 2.51 ± 0.06% and 6.92 ± 0.25%, respectively.
Early viral infection (⩽100 days)
At a median of 34.5 days (range, 19-68), CMV infection developed in 42 patients with a CI of 84.00 ± 0.29%, and CMV disease only occurred in one patient (enteritis). Eight patients experienced EBV infection at a median of 42.5 days (range, 21-54) with a CI of 16.00 ± 0.27%. EBV-related post-transplant lymphoproliferative disorder was identified in one patient.
Regimen-related toxicity and transplantation-related mortality In our cohort, grades 3-4 regimen-related toxicity occurred in four patients (7.8%) that included two cases (3.9%) each of central nervous system and cardiac toxicity. In terms of cerebral toxicity, two cases suffered epileptic seizure on days 01 and 02, respectively. Besides, early-onset haemorrhagic cystitis was found in two cases (3.9%) with grade 2. Late-onset hemorrhagic cystitis occurred in 18/51 (35.3%) adults. The majority of patients (25.5%) had grades 1 and 2 late-onset hemorrhagic cystitis. Grade 3 lateonset hemorrhagic cystitis was noted in five (9.8%) patients. All patients recovered after conservative treatment.
Eight patients died with a median time of 73.5 days (range, 1-217). Of these, seven patients died of TRM, and the remaining patient suffered an accidental death while travelling on day 84. The CI of TRM was 13.73 ± 0.24%. The cause of TRM was related with severe GVHD, infection and cardiotoxicity in one, four and two cases, respectively.
Survival outcomes
Upon follow-up for 3.2 to 71.1 months, the probabilities of 1-and 3-year OS were 83.5 ± 5.4%. As none of the patients experienced disease graft failure, relapse or clonal evolution, consequently, the probabilities of FFS were equal to the OS.
Risk factors for survival and GvHD
The analyses for factors predicting the probabilities of survival outcomes are shown in Supplementary Table 1. The 3-year probabilities of OS were 84.2% and 81.5% in patients aged 18-29 years and430 years, respectively (P = 0.919). The 3-year OS were 64.8% and 87.7%, respectively, in patients with ATG and without ATG (P = 0.122). In univariate analyses, lower infusions of CD4 (P = 0.017) and CD8 (P = 0.023) cells were regarded as adverse predictors. Moreover, a lower trend of survival was observed in patients who had HCT-CI of ⩾ 3 (86.8 vs 50.0%; P = 0.058). In multivariate analysis (Table 2) , only HCT-CI of ⩾ 3 was significantly associated with worse outcomes (hazard ratio, 5.573 (95% confidence interval, 1.070-29.016); P = 0.041) (Figure 1) .
Univariate analyses for II-IV and III-IV aGVHD were shown in Supplementary Table 2 . In univariate analysis, a lower CD4/CD8 ratio (o 1.2) in the bone marrow resulted in a lower incidence of II-IV aGVHD than that of CD4/CD8 ⩾ 1.2 (8.33% vs 30.77%, P = 0.047). For III-IV aGVHD, significance was observed with the increase in severity of the disease (0% in SAA group and 23.08% in vSAA group, P o 0.003). However, we did not perform multivariate analysis on II-IV and III-IV aGVHD because the other factors did not demonstrate a P o0.1 in the univariate analysis.
DISCUSSION
Haploidentical transplantation for aplastic anaemia was not widely accepted previously because of the increased frequency of engraftment failure and severe GVHD during early attempts. 31, 32 However, considerable improvement has been implemented in recent years. Here, we demonstrate that HID-SCT conditioning with Bu/Cy/ATG resulted in favourable engraftment (98.0%), acceptable incidences of grade II-IV (20.0%) and chronic GVHD (25.9%) at 3 years, and improved OS and FFS (83.5% at 3 years) in SAA adults. To the best of our knowledge, this study describes the Abbreviations: FSS = failure-free survival; HCT-CI = hematopoietic cell transplantation-specific comorbidity index; OS = overall survival. outcome of the largest single-centre cohort of adult SAA patients who received HID-SCT. Although various conditioning regimens of HID-SCT have been shown to be effective in successful engraftment with decreased mortality, an optimal conditioning regimen has not yet been established. [9] [10] [11] [12] [13] [14] The current EBMT SAAWP protocol recommends the use of non-myeloablative conditioning with Cy, fludarabin (Flu), TBI and a high dose Cy post-graft. 4 Previous studies that utilized this regimen reported primary graft failure rates of 6-25%. 13, 14 Im et al. reported PGF rates of 4.8-8.3% of ex vivo T-cell-depleted grafts following a conditioning regimen of Flu/Cy/ ATG ± TBI. 10, 33 The present cohort study compared favourably with these other approaches. In our previous multicentre studies, patients surviving for more than 28 days, 97/97 (100%) in salvage cohort and 87/88 (98.9%) in upfront cohort, achieved donor type engraftment demonstrating the application of Bu/Cy/ATG significantly benefited successful engraftment. 16, 17 In the present single-centre study, primary graft failure was not observed in the adult patients further supporting the feasibility of our regimen. As was stated previously, a few unique aspects of our protocol might be useful to promote stable engraftment, which included the addition of Bu to the standard conditioning regimen (Cy+ATG) in MRD HSCT, the combination of G-BM and G-PB grafts and the application of a more potent GVHD prophylactic strategy. 9, 26 Considering that the age of patients at the time of transplant has been identified as an important factor for the outcomes of allo-SCT owing to the inferior tolerability observed in older patients, studies have increasingly focused on identifying regimens that improve the outcome of adults after transplantation, especially post MRD and matched unrelated donor, respectively. 22, 34, 35 A recent retrospective study by Shin et al.
35
reported the estimated FFS and OS rates at 5 years in adults who received Flu/lower-dose Cy/ATG conditioning regimen following MRD-SCT were 77.2% and 91.5%, respectively. Lee et al.
22
observed 5-year estimated OS of 88.0% in unrelated SCT with TBI-800/Cy-120. Nevertheless, reports of SAA adults receiving HID-SCT are relatively uncommon. A multicentre retrospective study on 26 adult SAA patients showed an OS rate of 84.6% after HID-SCT using Flu/Cy/ATG. 11 Recently, a study from Korea observed a 5-year survival rate of 48.2% in HID group with Bu/Flu/ATG; although this was slightly lower than that of the alternative donor group (61.3%), this difference was not significant. 8 The present study revealed excellent 3-year OS and FFS (83.5%) that was comparable with the data of previous reports of SCT from MRD, matched unrelated donor, and HID, respectively. However, our observations differ from those of Gupta et al., who reported that mortality risk significantly increased with age in identical sibling recipients. 34 In the current study, the 3-year probabilities of OS were 84.2% and 81.5% in patients aged 18-29 years and 430 years, respectively (P = 0.919). An explanation for our results could be that the applied regimen reduced the negative effects of age in these SAA adults, but sampling from a larger cohort would be required for further confirmation. Another aspect that should be noted is that age distribution in our patient cohort was relatively small, owing to the exclusion of children and young adolescents, and the low number of enrolled patients being over 40 years (n = 6).
Among the factors affecting survival outcomes, HCT-CI was significant in this study. HCT-CI has been previously reported as a predictive factor of survival across different haematological malignancies post-transplantation from different donors. [36] [37] [38] Mo et al. 38 in their large cohort of haploidentical recipients reported that the probabilities of all-cause mortality were significantly elevated in patients with HCT-CI scores of ⩾ 3. However, only few studies have assessed this factor independently in SAA subjects. In our cohort, patients with HCT-CI scores of ⩾ 3 had a significantly poorer 3-year OS than patients with HCT-CI scores of 0-2 (86.8% vs 50.0%). Thus, we considered that HCT-CI might be a valuable tool to assess OS risk in SAA adults, especially for patients when deciding between transplantation and immunosuppressive therapy. However, in transplantation patients, further investigations to evaluate lowering the intensity of applied conditioning regimens in high-risk patients with comorbidities are essential to further improve the outcomes. We demonstrated that a larger CD4/CD8 ratio with the cut-off value of 1.20 bone marrow (BM) was a potential risk factor that predicted the occurrence of grade II-IV aGvHD in SAA. Our result was supported by a retrospective study by Luo et al. who reported that CD4/CD8 ratio ⩾ 1.16 in primed BM significantly correlated with an increased incidence of grade II-IV aGVHD. 39 Recently, a controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute GVHD was also conducted directed by BM CD4: CD8 ratios in haematologic neoplasms after HID-SCT. 40 Future studies are required to determine the optimal cut-off of BM CD4/ CD8 in SAA patients; thus, the incidence of aGVHD could be further reduced under risk-stratified prophylaxis.
With respect to the safety of our conditioning regimen, we observed two cases of cardiotoxicity-related death. We also observed common characteristics between the two deceased patients, such as a history of increased RBC transfusions and longer interval between diagnosis and transplantation. Furthermore, our conditioning regimen might have been quite intensive leading to the increased prevalence of CMV viraemia in our cohort. However, intensive myelosuppression to facilitate successful engraftment might be necessary in SAA; the management of viraemia in our cohort was profoundly successful with only one patient developing CMV disease.
Our study was limited by a small sample size, retrospective analysis, and a relatively short follow-up period of some of the patients. Moreover, some factors were not significant, probably owing to the small number of patients in each group. Besides, our median age is very young to tolerate busulfan, and the toleration in elderly population remains unknown. Further studies including more elderly cases are needed to prove that.
In summary, our results suggest that conditioning regimen including Bu/Cy/ATG could be applicable to adults with SAA, and that HCT-CI could be used as a predictor for post-treatment outcome in these patients. Our data further proved that haploidentical transplantation without in vitro T-cell depletion was a feasible strategy for adult SAA patients, with successful engraftment, acceptable GvHD and improved survival outcomes.
